Lung cancer has been the forgotten cancer for far too long. Research grants like this are a critical first step towards giving hope to the patients, families and friends of those affected by this insidious disease." Kim Norris, President, LCFA
Los Angeles, CA (PRWEB) December 21, 2009
Lung cancer, the nation’s leading cause of cancer deaths for women and men, remains the most under-funded, under-researched and under-supported cancer. There are currently no approved early detection tests for lung cancer. With a 5-year survival rate of only 15%, the prognosis for lung cancer has not changed in 40 years. A new organization, Lung Cancer Foundation of America (LCFA) is trying to change this reality, and save lives by dramatically increasing the five-year survival rate for all stages of lung cancer. LCFA will accomplish this by providing the necessary and critical funding for creative and leading edge lung cancer research programs.
Barely two years old, LCFA is proud to partner with the International Association for the Study of Lung Cancer (IASLC) in announcing its inaugural Request for Proposal for a research award in the amount of $125,000 this Holiday Season. LCFA and IASLC are partnering to fund exciting lung cancer research opportunities for molecular analysis of bio-specimens (blood, tissue, urine, etc.) collected as part of medium to large clinical trials.
“Lung cancer has been the forgotten cancer for far too long,” said Kim Norris, the President of LCFA. “Research grants like this are a critical first step towards giving hope to the patients, families and friends of those affected by this insidious disease. But much more needs to be done to save lives.”
Current public and private funding for lung cancer mostly focuses on prevention, which is only one part of the equation. Early detection and treatment are just as critical, especially because it is estimated that 60% of new lung cancer diagnoses will be in non-smokers - a combination of 45-50% former smokers (many who quit 10, 20, even 30 years prior to the onset of lung cancer) and people who have never smoked. These former smokers did the right thing … they quit. Little do they know that they are still at risk for lung cancer and just like lung cancer victims who have never smoked, they will be shocked to discover how few treatment options are available to them. In 2009 more than 214,000 people in this country will be diagnosed with lung cancer and more than 157,000 will die from it.
LCFA is one of only a handful of private foundations devoted to the research of early detection and treatment of lung cancer. As of 2006, there were less than 30 lung cancer specific foundations providing lung cancer research grants, all of which combined did not give more than $5 million dollars in grant money. At the same time, this year, lung cancer will claim more lives than breast, prostate, colon, liver, kidney and melanoma cancers – COMBINED, all of which underscores the importance of this grant and others like it.
LCFA was established by two lung cancer survivors and a lung cancer widow. Although their life experiences vary greatly the three of them have come to the same realization…the poor survival rate for lung cancer is a direct result of the lack of funding for lung cancer research. Working with many of the top lung cancer researchers and clinicians in this country, LCFA has seen how lung cancer researchers are trying diligently to unlock the secrets unique to lung cancer. They have also witnessed the inordinate amount of time researchers spend in an effort to secure money to pay for the research, an effort that distracts them from their primary research function. The abysmal state of funding for lung cancer research also discourages new researchers who, instead, gravitate to where the money is, leaving a potential gaping hole in future lung cancer research programs. LCFA's mission is to save lives by dramatically increasing the five-year survival rates for all stages of lung cancer, the nation's leading cause of cancer deaths for both men and women. LCFA will accomplish this by providing the necessary and critical funding for creative and leading edge lung cancer research programs. http://lcfamerica.org/
For more information contact Rachel Schwartz at PR AdvantEDGE, Inc., http://pr-a.biz/.